Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
297 participants
INTERVENTIONAL
2005-02-28
2007-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ICA-17043
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female (not capable of becoming pregnant or using appropriate birth control)
* Medical history of sickle cell disease
* Have a history of at least two or more acute sickle-related painful crises requiring a visit to a medical facility within the preceding 12 months
Exclusion Criteria
* On a chronic transfusion program
* Has significant active and poorly controlled (unstable) cardiovascular, neurologic, endocrine, hepatic, or renal disorders clearly unrelated to sickle cell disease
16 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
INDUSTRY
Icagen
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jonathan W Stocker, Ph.D.
Role: STUDY_DIRECTOR
Icagen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mobile, Alabama, United States
Little Rock, Arkansas, United States
Davis, California, United States
Los Angeles, California, United States
Oakland, California, United States
Denver, Colorado, United States
Hartford, Connecticut, United States
Washington D.C., District of Columbia, United States
Holly Hill, Florida, United States
Hollywood, Florida, United States
Jacksonville, Florida, United States
Augusta, Georgia, United States
Savannah, Georgia, United States
Chicago, Illinois, United States
Iowa City, Iowa, United States
New Orleans, Louisiana, United States
Shreveport, Louisiana, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Detroit, Michigan, United States
Jackson, Mississippi, United States
Kansas City, Missouri, United States
Las Vegas, Nevada, United States
Hackensack, New Jersey, United States
New Brunswick, New Jersey, United States
Newark, New Jersey, United States
Brooklyn, New York, United States
The Bronx, New York, United States
Chapel Hill, North Carolina, United States
Durham, North Carolina, United States
Greenville, North Carolina, United States
Winston-Salem, North Carolina, United States
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Charleston, South Carolina, United States
Memphis, Tennessee, United States
Nashville, Tennessee, United States
Houston, Texas, United States
San Antonio, Texas, United States
Richmond, Virginia, United States
Porto Alegre, , Brazil
Rio de Janeiro, , Brazil
São Paulo, , Brazil
Créteil, , France
Kingston, , Jamaica
Port of Spain, , Trinidad and Tobago
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Stocker JW, De Franceschi L, McNaughton-Smith GA, Corrocher R, Beuzard Y, Brugnara C. ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood. 2003 Mar 15;101(6):2412-8. doi: 10.1182/blood-2002-05-1433. Epub 2002 Nov 14.
Related Links
Access external resources that provide additional context or updates about the study.
Icagen webpage
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ICA-17043-10
Identifier Type: -
Identifier Source: org_study_id